Katherine Olson, PhD

Kate_Olson.pngKatherine Olson, PhD
Instructor


 

Laboratory: Howard E. Gendelman, MD
Movement Disorders Laboratory

Durham Research Center
985800 Nebraska Medical Center
Omaha, NE 68198-5800

 

Keywords: Neurodegeneration, Neuroprotection, Immunomodulation, Parkinson’s disease, Regulatory T Cells, Neuroimmunology, Neuroinflammation


 

In the News
Research Interests
Ongoing Projects
Representative Publications

In the News:

Omaha World Herald | May 31, 2021
UNMC researchers identify better-tolerated therapy for Parkinson's disease

UNMC Today | May 19, 2021
Immune transformation shows promise for Parkinson's disease

UNMC Today | May, 11, 2021
UNMC, Moderna study explores Parkinson's therapy

UNMC Today | April 27, 2018
Awards recognize research in aging diseases

UNMC Today | March 24, 2017
UNMC scientists achieve research milestone with Parkinson's disease

UNMC Today | December 16, 2015
UNMC teams on Parkinson's disease preclinical study


Research Interests:  

The focus of my research is to investigate the interplay between the innate and adaptive immune system, and its role in neurodegeneration and neuroprotection. I am currently working to develop neurotherapeutic approaches for a broad spectrum of neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). AD and PD are the two most common forms of neurodegenerative disease, and they have few effective therapeutic treatments. Genetic factors, environmental cues, increased age, and aberrant immune responses have all been associated with their progression and enhanced neurodegeneration.  To date, there is little known about the etiology of the diseases, treatments only address symptoms, and there is no known cure or therapy available to halt disease progression. Therefore, it remains imperative that therapies are developed focusing on combating the cause of neurodegeneration rather than simply alleviating symptoms. A major contributor to disease progression is abnormal innate and adaptive immune responses that affect the tempo of disease and lead to enhanced neuronal loss resulting in an overactive inflammatory response in the brain that leads to observable clinical manifestations. Previously, our laboratory has investigated the role of effector T cell and regulatory T cell subsets within the adaptive immune system eliciting either degenerative or protective roles depending on their phenotype. Therefore, our main focus is on the role of regulatory T cell-mediated immunosuppression and its ability to modulate the brain microenvironment either directly or indirectly.


Ongoing Projects:

  1. Clinical evaluation of sargramostim (GMCSF) in Parkinson’s disease patients.

GM-CSF has been safely used in the clinical setting to repopulate myeloid cell populations following chemotherapy, but it has also been realized that GM-CSF has the potential to act in both the CNS and on the peripheral immune system. Using an animal system, we were able to display the immune modulating capabilities of GM-CSF by eliciting a neuroprotective response in MPTP-induced nigrostriatal injury. We also found that GM-CSF acts by modulating the innate and adaptive immune response by increasing Treg-mediated control of neuroinflammation. Due to these promising findings, we utilized GM-CSF as a therapeutic strategy for targeting Treg function in humans suffering from PD. With GM-CSF treatment, we observed an increased frequency of Treg within the peripheral blood population, coinciding with an increase in functional Treg response, as well as Unified Parkinson’s Disease Rating Scale Part III (UPDRS III) score improvements. As a whole, treatment has the ability to induce an immune transformation from a neurotoxic response to a protective regulatory response, suggesting that targeting the neuroinflammatory immune response associated with PD progression is a beneficial therapeutic strategy. We are currently evaluating modified dosing and administration schemes to enhance efficacy and reduce untoward side effects.

 

  1. Development and pre-clinical assessment of immunotherapies in rodent models of Parkinson’s disease.

In order to continue developing highly effective and clinically-appealing therapies, we have started assessing the potential of using other immune-modulating agents, as well as continuing assessments of GM-CSF within in our rodent models of PD and AD. We utilize 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and alpha-synuclein overexpression in mice and rats to assess immune phenotypes, disease progression, inflammatory responses, and neuroprotective capacity following treatment with various drugs.


Publications:

  1. Kosloski, LM., Kosmacek, E.A., Olson, K.E., Mosley, RL., Gendelman, H.E. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. Journal of Neuroimmunology. 2013; 265: 1-10.
  2. Anderson, K.M.*, Olson, K.E.*, Estes, K.A., Flanagan, K., Gendelman, H.E., Mosley, R.L. Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Translational Neurodegeneration. 2014; 3: 25. *shared first author
  3. Olson, K.E., Gendelman, H.E. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson’s disease. Current Opinion in Pharmacology. 2015: 26:87-95.
  4. Olson, K.E., Kosloski-Bilek, L.M., Anderson, K.M., Diggs, B.J., Clark, B.E., Gledhill, J.M, Shandler, S.J., Mosley, R.L., Gendelman, H.E. Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated mice. Journal of Neuroscience, 2015: 35:50.
  5. Olson, K.E., Bade, A., Schutt, C, Dong, J., Boska, MD, Shandler, S., Mosley, R.L., Gendelman, H.E., Yutong, L. Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson’s Disease. Neurotherapeutics, 2016 13:635-46.
  6. Gendelman, H.E., Zhang, Y., Santamaria. P., Olson, K.E., Schutt, C., Bhatti, D., Dyavar Shetty, B.L., Lu, Y., Estes, K.A., Standaert, D.G., Heinrichs-Graham, E., Larson, L., Meza, J.L., Follett, M., Forsberg, E., Wilson, T.W., Peterson, C., and Mosley, R.L. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinsons disease trial. Nature: Parkinson’s Disease, 2017 3:10.
  7. Olson, K.E, Bade, A., Namminga, K., Potash, M.J., Volsky, D, Mosley, R.L., Poleuktova, L, and Gendelman, H.E. Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. Journal of NeuroVirology, 2018 24:398-410.
  8. Mosley, R.L, Lu, Y., Olson, K.E., Macchi, J., Yan, W., Namminga, K.L., Smith, J., Shandler, S., and Gendelman, H.E. A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease. Frontiers in Cellular Neuroscience. 2019.
  9. Schwab, A.D., Thurston, M.J., Machhi, J., Olson, K.E., Namminga, K.L., Gendelman, H.E., and Mosley, R.L. Immunotherapy for Parkinson's disease. Neurobiology of Disease, Epub.
  10. Macchi, J., Kevadiya, B, Muhammad, I.K., Herskovitz, J., Olson, K.E., Mosley, R.L., and Gendelman, H.E. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Molecular Neurodegeneration 2020.
  11. Olson, K.E., Namminga, K.L., Schwab, A., Thurston, M., Lu, Y., Woods, A., Lei, L., Shen, W., Wang, F., Joseph, S.B., Gendelman, H.E., and Mosley, R.L. Neuroprotective Activities of Long-Acting Granulocyte–Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice. Neurotherapeutics

Additional publications in PubMed

Top of page.